MOTS-c Peptide Research: Mitochondrial Signaling, AMPK and Evidence

Updated August 2026. MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within a short open reading frame in mitochondrial 12S rRNA. It was first described in 2015 as a signaling peptide involved in metabolic homeostasis, with early work linking its cellular effects to folate-cycle disruption, AICAR accumulation and activation of AMP-activated protein kinase (AMPK).

MOTS-c is unusual because it links mitochondrial genetics with cell-wide signaling. Research shows that metabolic stress can promote its movement to the nucleus, where it participates in regulation of stress-responsive genes. This article reviews the mechanism, exercise and skeletal-muscle findings, metabolic research, human evidence and the major limitations of the current literature.

MOTS-c at a Glance

Feature	Research description
Length	16 amino acids
Origin	Encoded by a short open reading frame within mitochondrial 12S rRNA
Peptide class	Mitochondrial-derived peptide (MDP)
Core pathway	Folate-AICAR-AMPK signaling
Major research areas	Metabolic homeostasis, skeletal muscle, stress adaptation, mitochondrial function, exercise and aging-related biology
Human evidence	Observational and exercise studies plus an ongoing Phase 2a metabolic trial; most mechanistic efficacy data remain preclinical

What Is MOTS-c?

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. Its discovery helped expand the idea that mitochondrial DNA does more than encode components of cellular energy production: it can also encode small signaling peptides capable of influencing physiology beyond the mitochondrion itself.

The original 2015 study identified MOTS-c as a 16-amino-acid peptide and reported effects on insulin sensitivity and metabolic homeostasis in mice, with skeletal muscle emerging as a particularly important target tissue.

The Folate-AICAR-AMPK Pathway

The best-characterized MOTS-c mechanism begins with one-carbon and purine metabolism. The discovery work reported inhibition of the folate cycle and linked de novo purine biosynthesis, producing an increase in the AMP analogue AICAR. AICAR is a recognized activator of AMPK, a central cellular energy sensor.

AMPK responds to energetic stress by shifting cellular programs away from energy-consuming synthesis and toward pathways that restore energy balance. This provides a mechanistic bridge between MOTS-c and many of the metabolic outcomes examined in preclinical studies.

It is still too simplistic to describe MOTS-c only as an AMPK activator. Its stress-responsive nuclear activity shows that its biology extends beyond a single kinase pathway.

Mitochondria-to-Nucleus Signaling

A major advance came in 2018, when researchers showed that MOTS-c can translocate to the nucleus in response to metabolic stress. This movement was AMPK-dependent. Once in the nucleus, MOTS-c was associated with changes in expression of stress-responsive genes, including genes containing antioxidant response elements, and with transcription factors such as NRF2.

This makes MOTS-c particularly interesting as a model of mitochondrial retrograde signaling: information encoded by mitochondrial DNA can generate a peptide that feeds back onto the nuclear genome and alters cellular stress responses.

MOTS-c and Skeletal-Muscle Metabolism

Skeletal muscle has been a recurring focus in MOTS-c research. The original work identified muscle as a primary target tissue in mouse metabolic studies, and later experiments linked MOTS-c to exercise adaptation, metabolic stress resistance and physical capacity.

A 2021 study reported that endogenous MOTS-c increased with exercise in human skeletal muscle and circulation, while experimental MOTS-c improved physical performance and metabolic adaptation in mice across multiple ages. The authors also reported regulation of nuclear genes involved in metabolism and proteostasis.

More recent work published in 2026 examined intrinsic muscle mitochondrial bioenergetics and reported MOTS-c-related improvements in mitochondrial efficiency in a PGC-1α/AMPK-dependent experimental model.

Exercise and Endogenous MOTS-c in Humans

Human research is much more limited than the animal literature, but several studies have measured endogenous MOTS-c in relation to exercise. A human exercise study found that acute endurance exercise altered circulating mitochondrial-derived peptides, with MOTS-c showing a trend toward an increase, while other research has reported exercise-associated changes in skeletal-muscle MOTS-c expression.

These studies support the idea that MOTS-c participates in physiological responses to exercise. They do not establish that administering MOTS-c reproduces the full biological effects of exercise in humans.

That distinction matters because the popular description of MOTS-c as an exercise mimetic is considerably broader than the available human evidence.

Metabolic Homeostasis and Insulin-Sensitivity Research

Early mouse experiments reported protection against diet-induced obesity and insulin resistance, along with improved glucose handling. These findings drove much of the subsequent interest in MOTS-c as a metabolic signaling molecule.

Human observational studies have also examined circulating MOTS-c in metabolic conditions. Research in women with polycystic ovary syndrome and healthy controls found that lipid and insulin exposure altered circulating MOTS-c concentrations. Such findings show that endogenous MOTS-c responds to metabolic signals, but they do not establish therapeutic efficacy.

The 2026 Phase 2a MOTS-MET Trial

An important change in the evidence landscape is the launch of a formal Phase 2a randomized, double-blind, placebo-controlled study of MOTS-c in adults with prediabetes and overweight or obesity. ClinicalTrials.gov lists the study as NCT07505745.

The trial is designed to evaluate 12 weeks of investigational MOTS-c, with insulin sensitivity as a major efficacy endpoint alongside metabolic markers and safety assessments. The study began in February 2026 and has an estimated enrollment of 120 participants. Primary completion is currently estimated for 2027.

As of August 2026, no results have been posted. The existence of a Phase 2 study therefore shows that MOTS-c has progressed into formal human investigation; it does not show that the trial has demonstrated benefit.

MOTS-c, Aging and Physical Capacity

MOTS-c has attracted attention in aging research because mitochondrial dysfunction, metabolic flexibility and loss of physical capacity are all associated with aging. In mouse studies, MOTS-c administration has been associated with improved physical performance in young, middle-aged and older animals, including late-life interventions.

These observations make MOTS-c a useful experimental tool for studying mitochondrial signaling and age-related metabolic adaptation. They do not justify treating preclinical healthspan findings as established human anti-aging effects.

AMPK, PGC-1α and Mitochondrial Biogenesis

AMPK and PGC-1α repeatedly appear in MOTS-c research. AMPK is an energy-sensing kinase, while PGC-1α is a transcriptional coactivator strongly involved in mitochondrial biogenesis and oxidative metabolism.

Studies in exercise, muscle and disease models have reported MOTS-c-associated activation of the AMPK/PGC-1α axis. A 2026 muscle-bioenergetics paper further supports dependence of some mitochondrial effects on these pathways. Pathway activation in an experimental system, however, is not proof of a specific clinical outcome.

Stress Adaptation and NRF2-Related Signaling

The nuclear-translocation literature suggests another important role for MOTS-c: cellular stress adaptation. During glucose restriction and other metabolic stress, MOTS-c can move into the nucleus and interact with stress-responsive transcriptional machinery, including pathways involving antioxidant response elements and NRF2.

This supports a broader model in which MOTS-c participates in mitochondria-to-nucleus communication and helps coordinate adaptive gene-expression programs.

What Does the Evidence Actually Support?

The strongest conclusions are mechanistic. MOTS-c is a genuine mitochondrial-derived peptide; it is encoded by mitochondrial DNA, can participate in AMPK-linked metabolic signaling, can translocate to the nucleus during metabolic stress, and has reproducible preclinical effects across several metabolic and muscle models.

Human research demonstrates that endogenous MOTS-c can be measured and can respond to metabolic or exercise-related conditions. A formal Phase 2a trial is now underway. What is not yet established is a broad human efficacy profile for externally administered MOTS-c across obesity, longevity, exercise performance or other popular claims.

Evidence Limitations

• Much of the efficacy literature remains based on cell and animal models.
• Human exercise studies generally examine endogenous MOTS-c rather than therapeutic administration.
• Associations between circulating MOTS-c and metabolic traits do not prove causation.
• The ongoing Phase 2a metabolic trial has not yet reported results as of August 2026.
• AMPK activation is a mechanistic finding, not proof of a particular clinical outcome.
• The term exercise mimetic should not be interpreted as evidence that MOTS-c reproduces all effects of exercise in humans.

MOTS-c Research Product

Peps In Bulk maintains a separate MOTS-c research product page for current pack, strength and certificate information. This article covers the scientific background and evidence rather than duplicating product-page purchasing content.

For broader background on peptide science, research standards and analytical quality, see our Peptides: Science, Market Forces, and Research Quality Standards guide.

Frequently Asked Questions

What does MOTS-c stand for?

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a 16-amino-acid mitochondrial-derived peptide.

Is MOTS-c encoded by mitochondrial DNA?

Yes. MOTS-c is encoded within a short open reading frame located in mitochondrial 12S rRNA.

How is MOTS-c connected to AMPK?

Research links MOTS-c to changes in folate and purine metabolism, increased AICAR and downstream activation of AMPK. AMPK is also involved in MOTS-c nuclear translocation during metabolic stress.

Can MOTS-c enter the nucleus?

Experimental research shows that metabolic stress can trigger AMPK-dependent nuclear translocation of MOTS-c, where it can influence stress-responsive gene expression.

Has MOTS-c been studied in humans?

Yes, but the human evidence remains limited. Studies have examined endogenous MOTS-c during exercise and metabolic conditions, and a Phase 2a randomized trial in adults with prediabetes and overweight or obesity began in 2026.

Does MOTS-c have proven anti-aging or exercise-performance effects in humans?

No broad human efficacy conclusion has been established. Many of the strongest aging and performance findings come from animal studies, while human interventional research is still developing.

Primary and Review Sources

1. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015.
2. Kim KH, et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism, 2018.
3. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021.
4. Wan W, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging, 2023.
5. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner, 2026.
6. ClinicalTrials.gov: MOTS-MET Phase 2a study, NCT07505745.

Featured photo: National Cancer Institute via Unsplash.